ADVENTRX Announces Further Cost-Cuttin...(d marketing ANX-530 and ANX-514 includin...)

Date:1/5/2009

d marketing ANX-530 and ANX-514, including validating commercial manufacturers and suppliers and the potential for automatic injunctions regarding FDA approval of ANX-514; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings, including prior to the submission or the approval of an NDA for ANX-530 and ANX-514; the risk that the performance of third parties on whom ADVENTRX relies to conduct its studies or evaluate the data, including clinical investigators, expert data monitoring committees, contract laboratories and contract research organizations, may be substandard, or they may fail to perform as expected; the risk that ADVENTRX's stockholders will not approve a strategic or capital-raising transaction recommended by ADVENTRX's Board of Directors; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.

'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. ADVENTRX Exploring Strategic Options
2. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
3. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
4. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
5. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
6. ADVENTRX Settles Dispute With Former Licensee
7. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. ADVENTRX Appoints Vice President of Manufacturing
9. ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
10. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
11. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results